8-K: Aprea Therapeutics Reports Promising Clinical Trial Updates and Third Quarter 2024 Financial Results

Aprea Therapeutics announced positive preliminary results from its Phase 1 trial of APR-1051, a WEE1 inhibitor, and provided updates on its ATR inhibitor, ATRN-119, along with its third quarter 2024 financial results.

Summary

• Aprea Therapeutics reported its financial results for the third quarter ended September 30, 2024, and provided a business update.
• The company has two clinical-stage therapeutic candidates, APR-1051 and ATRN-119, both showing promising results.
• Preliminary results from the Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor, indicate it is well-tolerated with no unexpected toxicities.
• Enrollment in the ACESOT-1051 trial is ahead of schedule, and the trial has begun enrolling at Cohort 4 (50 mg).
• Preliminary efficacy data from the ACESOT-1051 trial is expected in the first half of 2025.
• The Phase 1/2a ABOYA-119 study evaluating ATRN-119, an ATR inhibitor, is ongoing, with a twice-daily dosing regimen added to optimize dosing.
• As of October 2, 2024, 14 of 20 patients in the ABOYA-119 trial experienced adverse events possibly related to ATRN-119, but no serious adverse events or dose-limiting toxicities were observed.
• The company expects the ABOYA-119 Phase 1 readout to be available in the second half of 2025.
• Aprea had $26.2 million in cash and cash equivalents as of September 30, 2024, which is expected to fund operations for at least twelve months.
• The company reported an operating loss of $4.1 million for the third quarter of 2024, compared to a $3.5 million loss in the same period of 2023.
• The net loss for the quarter was $3.8 million, or $0.64 per basic share, compared to a net loss of $3.2 million, or $0.86 per basic share, in the third quarter of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical trial results and a solid cash position. However, the company is still in the early stages of development and faces risks, which tempers the overall sentiment.

Positives

• The WEE1 inhibitor, APR-1051, is showing promising tolerability in early trials.
• The company has a strong cash position of $26.2 million, providing a cash runway for at least twelve months.
• The company is making meaningful progress advancing its pipeline of two clinical-stage therapeutic candidates.
• The company is ahead of schedule with the enrollment of the Phase 1 ACESOT-1051 trial.
• The addition of a twice-daily dosing regimen in the ABOYA-119 trial could optimize the drug's effectiveness.
• Preliminary signs of clinical benefit were observed in two patients treated with ATRN-119 at low doses.
• The company has a strong intellectual property portfolio with four issued US patents.

Negatives

• The company reported an operating loss of $4.1 million for the third quarter of 2024.
• The net loss for the quarter was $3.8 million, or $0.64 per basic share.
• 14 of 20 patients in the ABOYA-119 trial experienced adverse events possibly related to ATRN-119, although no serious adverse events were reported.
• The company is still in the early stages of clinical trials, and there is no guarantee of success.

Risks

• The success of the clinical trials for APR-1051 and ATRN-119 is not guaranteed.
• The company may need to raise additional capital in the future to fund its operations.
• There are risks associated with the development and commercialization of new drugs, including regulatory hurdles and market acceptance.
• The company's financial results are subject to fluctuations and may be affected by various factors.
• The company is dependent on the success of its two lead programs, APR-1051 and ATRN-119.

Future Outlook

The company believes its cash and cash equivalents will be sufficient to fund operations for at least twelve months. Preliminary efficacy data from ACESOT-1051 is expected in the first half of 2025, and the ABOYA-119 Phase 1 readout is expected in the second half of 2025.

Management Comments

• We continue to make meaningful progress advancing our pipeline of two clinical stage therapeutic candidates as well as strengthening our clinical team, said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea.
• We are ahead of schedule with the enrollment of the Phase 1 ACESOT-1051 trial evaluating our next generation WEE1 inhibitor, APR-1051.

Industry Context

Aprea is operating in the precision oncology space, focusing on synthetic lethality. The company's WEE1 and ATR inhibitors are targeting unmet medical needs in cancers with specific genetic alterations. The company is competing with other companies developing similar inhibitors, but is attempting to differentiate itself with improved safety and tolerability profiles.

Comparison to Industry Standards

• Aprea's WEE1 inhibitor, APR-1051, is being developed to address tolerability issues seen with other WEE1 inhibitors like Adavosertib (AZD-1775) from AstraZeneca, which was discontinued due to its tolerability profile.
• Aprea's ATR inhibitor, ATRN-119, is a macrocyclic inhibitor, which is designed to improve selectivity and tolerability compared to first-generation acyclic ATR inhibitors like AZD6738 from AstraZeneca and BAY 1895344 from Bayer, which have shown hematological toxicities and intermittent dosing schedules.
• The company is aiming for a best-in-class profile for both APR-1051 and ATRN-119, with a focus on improved safety and continuous dosing, which is a key differentiator from competitors.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial updates and the company's financial position.
• Employees may be motivated by the progress of the company's pipeline.
• Patients with advanced solid tumors may benefit from the development of new treatment options.
• The company's suppliers and partners may see potential for future business opportunities.

Next Steps

• Aprea will continue enrollment in the ACESOT-1051 and ABOYA-119 clinical trials.
• The company expects preliminary efficacy data from ACESOT-1051 in the first half of 2025.
• The company anticipates the ABOYA-119 Phase 1 readout in the second half of 2025.
• The company will continue to optimize dosing and scheduling for both APR-1051 and ATRN-119.

Key Dates

Keywords

Aprea Therapeutics, APR-1051, ATRN-119, WEE1 inhibitor, ATR inhibitor, clinical trials, oncology, cancer, synthetic lethality, biopharmaceutical